{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:59Z","timestamp":1787026979854,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a potential therapeutic target. BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R\/R PTCL after at least one previous standard line of treatment (NCT03552692). Venetoclax given alone at a dosage of 800 mg\/day resulted in one complete response (CR) and two stable diseases (SDs) among 17 enrolled patients. The majority of patients (88.2%) interrupted the treatment due to disease progression. No relationship with BCL2 expression was documented. At a median follow-up of 8 months, two patients are currently still on treatment (one CR and one SD). No case of tumor lysis syndrome was registered. Therefore, venetoclax monotherapy shows activity in a minority of patients whose biological characteristics have not yet been identified.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>www.clinicaltrials.gov<\/jats:uri>\n                      (NCT03552692, EudraCT number 2017-004630-29).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.789891","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:59:57Z","timestamp":1638752397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed\/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi"],"prefix":"10.3389","volume":"11","author":[{"given":"Laura","family":"Ballotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Tisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Anna","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-Cell Lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","article-title":"A Systematic Review and Meta-Analysis of Front-Line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"D\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"ECHELON-2 Study Group. Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as Single Agent in Pretreated T-Cell Lymphoma Patients: Evaluation of the Long-Term Outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the Treatment of Relapsed\/Refractory Peripheral T-Cell Lymphoma: Pivotal Study Update Demonstrates Durable Responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective Responses in Relapsed T-Cell Lymphomas With Single-Agent Brentuximab Vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.09.002","article-title":"Peripheral T-Cell Lymphomas: Focusing on Novel Agents in Relapsed and Refractory Disease","volume":"60","author":"Broccoli","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L Expression in Nodal Peripheral T-Cell Lymphoma: Possible Biomarkers for Novel Targeted Therapies","volume":"92","author":"Zaja","year":"2017","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/path.1346","article-title":"BCL-2 Family Proteins in Peripheral T-Cell Lymphomas: Correlation With Tumour Apoptosis and Proliferation","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0127-z","article-title":"Clinical Role of Bcl-2, Bax, or P53 Overexpression in Peripheral T-Cell Lymphomas","volume":"85","author":"Jung","year":"2006","journal-title":"Ann Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 With Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and Obinutuzumab in Chronic Lymphocytic Leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-In-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a Valuable Tool to Assess CD30 Expression in Peripheral T-Cell Lymphomas: High Correlation With mRNA Levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol De M\u00e9dula \u00d3sea; German High-Grade Lymphoma Study Group; German Hodgkin\u2019s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and Mechanisms of Venetoclax Resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal Dynamics Towards the Development of Venetoclax Resistance in Chronic Lymphocytic Leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients With Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discovery"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 Mutations Cooccurring With Gly101Val Emerge in Chronic Lymphocytic Leukemia Progression on Venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells Is Associated With Poor Response to Chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and Preliminary Efficacy of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukaemia: A non-Randomised, Open-Label, Phase 1b Study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of Venetoclax as Targeted Therapy for Relapsed\/Refractory T(11;14) Multiple Myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:00:02Z","timestamp":1638752402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":27,"alternative-id":["10.3389\/fonc.2021.789891"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.789891","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"article-number":"789891"}}